Ardelyx Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ardelyx de 69.8% y 26.5% por año respectivamente. Se prevé que el BPA crezca en un 69.8% al año. Se espera que la rentabilidad financiera sea de 2.9% en 3 años.

Información clave

69.8%

Tasa de crecimiento de los beneficios

69.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	27.1%
Tasa de crecimiento de los ingresos	26.5%
Rentabilidad financiera futura	2.9%
Cobertura de analistas	Good
Última actualización	02 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Recent updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:ARDX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	531	130	160	165	9
12/31/2025	388	-13	57	42	10
12/31/2024	326	-42	N/A	-21	10
9/30/2024	252	-73	-64	-63	N/A
6/30/2024	210	-65	-86	-85	N/A
3/31/2024	159	-66	-81	-81	N/A
12/31/2023	124	-66	-90	-90	N/A
9/30/2023	134	-27	-67	-67	N/A
6/30/2023	83	-56	-71	-71	N/A
3/31/2023	63	-66	-87	-87	N/A
12/31/2022	52	-67	-70	-70	N/A
9/30/2022	9	-114	-124	-124	N/A
6/30/2022	5	-135	-133	-133	N/A
3/31/2022	4	-153	-137	-136	N/A
12/31/2021	10	-158	-154	-153	N/A
9/30/2021	11	-151	-133	-131	N/A
6/30/2021	12	-125	-118	-116	N/A
3/31/2021	13	-105	-102	-101	N/A
12/31/2020	8	-94	-82	-81	N/A
9/30/2020	8	-85	-75	-75	N/A
6/30/2020	8	-91	-76	-76	N/A
3/31/2020	6	-91	-85	-85	N/A
12/31/2019	5	-95	-77	-76	N/A
9/30/2019	3	-103	-84	-84	N/A
6/30/2019	0	-104	-91	-90	N/A
3/31/2019	0	-100	-81	-80	N/A
12/31/2018	3	-91	-71	-70	N/A
9/30/2018	45	-53	-47	-47	N/A
6/30/2018	44	-50	N/A	-39	N/A
3/31/2018	44	-53	N/A	-45	N/A
12/31/2017	42	-64	N/A	-65	N/A
9/30/2017	N/A	-106	N/A	-97	N/A
6/30/2017	N/A	-114	N/A	-102	N/A
3/31/2017	N/A	-117	N/A	-103	N/A
12/31/2016	N/A	-112	N/A	-93	N/A
9/30/2016	N/A	-98	N/A	-87	N/A
6/30/2016	N/A	-87	N/A	-75	N/A
3/31/2016	18	-50	N/A	-80	N/A
12/31/2015	24	-30	N/A	-72	N/A
9/30/2015	30	-16	N/A	-54	N/A
6/30/2015	38	2	N/A	-48	N/A
3/31/2015	29	-6	N/A	6	N/A
12/31/2014	32	-3	N/A	13	N/A
9/30/2014	34	-4	N/A	28	N/A
6/30/2014	33	-5	N/A	34	N/A
3/31/2014	31	-7	N/A	5	N/A
12/31/2013	29	-7	N/A	2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ARDX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que ARDX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ARDX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (26.5% al año) de ARDX crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (26.5% al año) de ARDX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ARDX sea baja dentro de 3 años (2.9%).

Ardelyx Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Consensus revenue estimates increase by 18%

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date pushed back to 2026

Price target increased by 7.1% to US$13.39

Recent updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Ardelyx: Strong Execution, Fairly Valued

Consensus revenue estimates increase by 18%

Insider notifies of intention to sell stock

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2026

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock